Total raised
$30.5M
Last: Series A 2026-01
Stage
Series A
Founded
2024
Headcount
28
HQ
Tel Aviv-Yafo
Sector
Health Tech & Life Sciences
About
Converge Bio is aiming is revolutionize biological R&D by creating a Generative AI platform for DNA, RNA, and protein sequences.
Funding history · 2 rounds · $30.5M total
2026-01
Series A
$25.0M
2024-11
Seed
$5.5M
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is Converge Bio's primary focus?
- Converge Bio is developing a Generative AI platform to revolutionize biological R&D for DNA, RNA, and protein sequences.
- When was Converge Bio founded?
- Converge Bio was founded in May 2024.
- Where is Converge Bio headquartered?
- Converge Bio is headquartered in Tel Aviv-Yafo, Israel.
- How many employees does Converge Bio currently have?
- Converge Bio has between 11 and 50 employees, with an exact count of 28.
- What was Converge Bio's first funding round?
- In November 2024, Converge Bio raised $5.5 million in Seed funding, with TLV Partners as an investor.
- What is Converge Bio's most recent funding round?
- In January 2026, Converge Bio completed a Series A funding round, raising $25 million. Bessemer Venture Partners was a lead investor.
- What is the total amount of funding Converge Bio has raised to date?
- Converge Bio has raised a total of $30.5 million across its funding rounds.
- Who is a founder of Converge Bio?
- Oded Kalev is a founder of Converge Bio.
- What technologies does Converge Bio utilize?
- Converge Bio utilizes Artificial Intelligence and Generative AI technologies.
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical Biotechnology
Technologies
Artificial IntelligenceGenerative AI
Target customers
Healthcare & Life SciencesLife SciencesBiotechnologyPharmaceuticals
Business model
B2B
Tags
pharmaceuticalsbiotechnologymolecular-biologyproteins